Pembrolizumab improved progression-free survival, second progression-free survival, and overall survival. Adding pembrolizumab to concurrent chemoradiotherapy (CCRT) can improve survival outcomes in ...

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...